Fresenius Medical Care - Champlin Chain: Fresenius Medical Care Location: 12339 Champlin Dr, Champlin, Minnesota, 55316 Rating: Phone: (763) 421-1032 |
News Archive
Pfizer Inc. announced today the discontinuation of the SUN 1120 Phase 3 trial evaluating SUTENT (sunitinib malate) in combination with prednisone for men with advanced castration-resistant prostate cancer that had progressed despite treatment with a docetaxel-based chemotherapy regimen. During a scheduled interim analysis, an independent Data Monitoring Committee found that the combination of sunitinib with prednisone was unlikely to improve overall survival when compared to prednisone alone.
A report on onchocerciasis (also known as river blindness) shows continued global progress towards achieving interruption of transmission of the disease.
Independent clinical trials, including one conducted at the Scheie Eye Institute at the Perelman School of Medicine, have reported safety and efficacy for Leber congenital amaurosis (LCA), a congenital form of blindness caused by mutations in a gene (RPE65) required for recycling vitamin A in the retina. Inherited retinal degenerative diseases were previously considered untreatable and incurable.
Maggot, or larval, therapy has been around since ancient times as a way to heal wounds. Now, the method has gone high-tech-in some ways-and it's being tested in a rigorous clinical trial at the Malcom Randall Veterans Affairs (VA) Medical Center in Gainesville, Fla. Recruitment is now underway.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today provided an update on its Phase 2 clinical trial for the use of its lead compound, NVC-422, to prevent urinary catheter blockage and encrustation which is often a contributing factor to urinary tract infections in chronically catheterized patients.
› Verified 6 days ago
Dialysis is used as a temporary measure in either acute kidney injury or in those awaiting kidney transplant and as a permanent measure in those for whom a transplant is not indicated or not possible. Dialysis facility in medicare covers outpatient maintenance dialysis treatments, training for self-dialysis, self-dialysis support services and self-dialysis equipment and supplies. In some cases, Medicare may cover ambulance transportation when the patient has End-Stage Renal Disease (ESRD), need dialysis, and need ambulance transportation to or from a dialysis facility.
The star rating shows how well a dialysis center delivers care compared to the national average, based on Medicare data. Each dialysis center receives a rating between 1 and 5 stars, with 3 stars representing the national average. A five-star rating means a center has quality of care that is considered 'much above average' compared to other dialysis facilities. A one or two-star rating means that measured health outcomes for that center were below average. The star rating is part of Medicare's work to make data on the quality of patient care easier to understand and use. Patient survey results aren't included in the star rating.